Stock Monitor: Incyte Post Earnings Reporting
LONDON, UK / ACCESSWIRE / February 20, 2018 / Active-Investors.com has just released a free research report on Asterias Biotherapeutics, Inc. (NYSE: AST) ("Asterias"). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=AST as the Company's latest news hit the wire. On February 15, 2018, the biotechnology Company, which is dedicated towards developing cell-based therapeutics for treating neurological conditions associated with de-myelination and cellular immunotherapies to treat cancer, declared that it has strengthened its global IP portfolio by issuing 46 new patents in the last year. Register today and get access to over 1000 Free Research Reports by joining our site below:
www.active-investors.com/registration-sg
Active-Investors.com is currently working on the research report for Incyte Corporation (NASDAQ: INCY), which also belongs to the Healthcare sector as the Company Asterias Biotherapeutics. Do not miss out and become a member today for free to access this upcoming report at:
www.active-investors.com/registration-sg/?symbol=INCY
Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Asterias Biotherapeutics most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:
www.active-investors.com/registration-sg/?symbol=AST
This announcement went well with investors as Asterias shares were up 3% premarket.
Details About Patents Issued
- The Company filed patents in the United States, Europe, Japan, Canada, China, Australia, Israel, and South Korea in the last 12 months. Of these 46 patents that were filed, 38 are owned or jointly owned by Asterias while eight patents are exclusively licensed to the Company.
- One of these patent covers the differentiation of pluripotent stem cells to hematopoietic progenitors and differentiation of pluripotent stem cells to immature and mature dendritic cells. This secures the patent rights for Asterias' second-generation allogeneic (non-patient specific) cancer immunotherapy AST-VAC2 (i.e. antigen-presenting allogeneic dendritic cells) program.
- Other patents include aspects of culture and expansion of undifferentiated stem cells, providing support for both its product candidates AST-VAC2 and AST-OPC1. AST-OPC1 (oligodendrocyte progenitor cells) is currently in a Phase-1/2a dose escalation clinical trial for treatment of severe spinal cord injury.
- Moreover, other patents cover differentiation of pluripotent stem cells to several other lineages, including neural cells such as dopaminergic neurons, cardiomyocytes, and hepatocytes.
Additional Patents to Enhance Shareholder Value
Michael Mulroy, President and Chief Executive Officer at Asterias, expressed his excitement about the new patents. He believes that these new patents would provide additional protection for certain properties of the AST-VAC2 manufacturing process. Alongside, it would also support scalable processes of culturing pluripotent stem cells.
These new patents and the complete patent portfolio would not only add value to the Company's programs but also offer future licensing and partnering opportunities with third parties, which will in turn, enhance shareholder value.
Asterias Announces Milestone Targets for 2018
Asterias Biotherapeutics provided its 2018 milestones targets for its spinal cord injury and cancer immunotherapy programs on January 04, 2018.
Milestones for AST-OPC1 – Spinal Cord Injury
The Company intends to report 6-month data from Cohort 3 (AIS-A 20 million-cell cohort) and Cohort 4 (AIS-B 10 million-cell cohort) in February 2018, and the 12-month data from Cohorts 3 and 4 in August 2018. It also expects to report the six-month top-line readout for the complete study in June 2018 and 12-month top-line readout in December 2018. Besides, Asterias also plans to continue discussions with the FDA to get clearance for the next study design of AST-OPC1.
Milestones for AST-VAC2 – Allogeneic Cancer Immunotherapy
Asterias intends to treat the first patient in 2018. The study will enroll around 24 patients into one of two cohorts on the basis of patient's stage of non-small cell lung cancer. The Company will report the initial safety and immunogenicity readouts in the second half of 2018, if the first-person treatment happens in the first half of 2018.
Stock Performance Snapshot
February 16, 2018 - At Friday's closing bell, Asterias Biotherapeutics' stock climbed 2.44%, ending the trading session at $2.10.
Volume traded for the day: 210.81 thousand shares, which was above the 3-month average volume of 201.09 thousand shares.
After last Friday's close, Asterias Biotherapeutics' market cap was at $111.01 million.
The stock is part of the Healthcare sector, categorized under the Biotechnology industry. This sector was up 0.6% at the end of the session.
Active-Investors:
Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
A-I has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the ''Author'') and is fact checked and reviewed by a third-party research service company (the ''Reviewer'') represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the ''Sponsor''), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: info@active-investors.com
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Active-Investors
